While BioStem continues to show operational and clinical progress with positive EBITDA and strategic growth plans, the significant revenue decline and reimbursement uncertainties present notable challenges. The sentiment is mixed, with strong financial metrics and future potential counterbalanced by current market and competitive pressures.

Company Guidance

During the BioStem Technologies Second Quarter 2025 Earnings Call, several key metrics and guidance points were discussed. The company reported $49.3 million in net revenue, representing a 34% decrease from $74.5 million in Q2 2024, primarily due to reimbursement uncertainties and increased competition from higher-priced products. Despite these challenges, BioStem achieved its sixth consecutive quarter of positive adjusted EBITDA and free cash flow, ending the quarter with $30.8 million in cash, an increase from $20.6 million in Q1. Gross profit stood at $48.6 million, with an impressive gross margin of 98.6%, supported by the product mix benefits of VENDAJE AC. Operating expenses decreased to $48.5 million, down from $61.9 million in the prior year. The company reported a GAAP net loss of $564,000 or $0.03 per share, compared to a net income of $6.3 million or $0.39 per share in Q2 2024. These results are set against the backdrop of ongoing initiatives, including a clinical trial for the BR-AC product and efforts to address potential changes in Medicare reimbursement rules. BioStem also reiterated its commitment to a strategic NASDAQ uplisting, which is part of its long-term growth strategy.

Positive Adjusted EBITDA and Free Cash Flow

BioStem delivered its sixth consecutive quarter of positive adjusted EBITDA and positive free cash flow, maintaining industry-leading gross margins.

Strong Cash Position

The company ended the quarter with $30.8 million in cash, an increase from $20.6 million in Q1 2025.

Clinical Trial Milestone

Completed patient enrollment in the clinical trial evaluating BR-AC for treating diabetic foot ulcers, with top-line results expected in Q4 2025.

Operational Expansion Plans

Plans to expand and diversify the product portfolio through R&D and acquisitions, and strengthening commercial presence.

NASDAQ Uplisting Progress

Pursuing uplisting to NASDAQ as part of a long-term strategic plan, which includes increased visibility and expanded access to capital.

BioStem Technologies (BSEM) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BSEM Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 18, 2025	2025 (Q3)	0.00 / -	0.32	―	―	―
Aug 14, 2025	2025 (Q2)	0.32 / -0.03	0.3	-110.00% (-0.33)	―
May 12, 2025	2025 (Q1)	- / 0.27	0.2	35.00% (+0.07)	―
Apr 14, 2025	2024 (Q4)	1.25 / 0.17	0.2	-15.00% (-0.03)	―
Nov 12, 2024	2024 (Q3)	0.36 / 0.32	0.03	966.67% (+0.29)	―
Aug 12, 2024	2024 (Q2)	0.27 / 0.30	0.07	328.57% (+0.23)	―
May 14, 2024	2024 (Q1)	- / -	-0.05	―	―
Apr 01, 2024	2023 (Q4)	0.74 / 0.20	-0.05	500.00% (+0.25)	―
Nov 13, 2023	2023 (Q3)	-0.18 / 0.03	-0.14	121.43% (+0.17)	―
Aug 22, 2023	2023 (Q2)	-0.02 / -0.20	0.02	-1100.00% (-0.22)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BSEM Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$10.38	$7.04	-32.18%
May 12, 2025	$15.20	$12.63	-16.91%
Apr 14, 2025	$12.89	$10.70	-16.99%
Nov 12, 2024	$24.72	$24.98	+1.05%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does BioStem Technologies Inc (BSEM) report earnings?

BioStem Technologies Inc (BSEM) is schdueled to report earning on Nov 18, 2025, During Market Hours (Confirmed).

What is BioStem Technologies Inc (BSEM) earnings time?

BioStem Technologies Inc (BSEM) earnings time is at Nov 18, 2025, During Market Hours (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BSEM EPS forecast?

BSEM EPS forecast for the fiscal quarter 2025 (Q3) is 0.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing